-
Jun 04 |
Diagnostics World News | A prominent urologic oncologist has helped develop a urine test found to be strikingly predictive of bladder cancer recurrence among patients undergoing surgery followed by BCG therapy, the current gold standard treatment regimen. The liquid biopsy also tends to identify recurrence risk that is missed by routine cystoscopy exams.
More
-
Jun 02 |
Diagnostics World News | At last month's Bio-IT World Conference & Expo, the opening plenary session featured an intimate series of paired conversations, each designed to place a different set of puzzle pieces on the table, examining that puzzle from four distinct vantage points — patient experience, AI-assisted diagnostics, venture investment, and policy reform — with each conversation delivering a bit more clarity to the emerging picture.
More
-
May 29 |
Diagnostics World News | Myriad Genetics launches the Prolaris + AI Test for prostate cancer; Lucent Diagnostics announce a collaboration with Tempus AI; Oxford Nanopore Technologies and Lonza launch new technology to modernize and accelerate GMP quality control testing for mRNA therapeutics; and more.
More
-
May 27 |
Diagnostics World News | At Scope X, Novo Nordisk gave a presentation on how high-impact opportunities for leveraging AI across the pharmaceutical R&D cycle are too numerous to count but won’t “automagically” solve any of the longstanding problems in ushering molecules to market. AI requires human attention to match tools to tasks for ensuring the accuracy of model predictions, and the pitfalls are dangerously easy to miss,
More
-
May 26 |
Diagnostics World News | Isomorphic Labs plans to continue development and deployment of its AI drug design engine; NVision expands POLARIS platform into quantum computation; Kanvas Biosciences advances commercial partnerships that leverage the company’s spatial imaging and manufacturing platform; and more.
More
-
May 21 |
Diagnostics World News | Researchers at the Oregon Health and Science University have established a rapid blood test to differentiate pancreatic cancer from other pancreatic conditions. The method involves the analysis of tumor-secreted nanoparticles on a specialized chip and actually outperforms the gold-standard needle-based biopsy diagnosis.
More
-
May 19 |
Diagnostics World News | For patients seeing a cardiologist, their diagnosis and next steps rest on data gathered at a single point in time: the day of their appointment. One blood pressure reading. One imaging scan. One day’s data to define the health of a continuously changing system. The Duke Center for Computational and Digital Health Innovation developed a platform that may be a better way.
More
-
May 14 |
Diagnostics World News | During pregnancy, the cells of a fetus make their way into the tissues of mom where they can persist for decades, much like what happens when someone gets an organ transplant but to a far tinier extent. That the maternal-fetal exchange results in chimerism—more specifically, “microchimerism”—is a relatively little-known yet fascinating and profoundly common biological phenomenon.
More
-
May 13 |
Diagnostics World News | An engaged research cohort of over 11 million genotyped individuals has enabled 23andMe to produce a library of more than 300 peer-reviewed publications over the past 16 years. Following a 2025 bankruptcy filing, when it reemerged as a nonprofit medical research organization, the focus has settled on providing individuals with access to their genetic information, supporting genetics education, and studies that provide a deeper understanding of human genetics.
More
-
May 12 |
Diagnostics World News | The diagnostics industry is at the intersection of enormous clinical development and technological change, enabling first-ever detection milestones heavily driven by artificial intelligence (AI) and multi-biomarker tests. But it has increasingly been coming into conflict with a decades-old regulatory system that didn’t anticipate these technological changes and a political environment that favors U.S. competition and innovation but is also interested in cutting the budget.
More
-
Jun 04 |
Moderna and Merck shared 5-year results from the KEYNOTE-942 study showing that their personalized mRNA cancer vaccine, intismeran autogene, combined with KEYTRUDA, significantly improves outcomes for high-risk melanoma patients. The treatment reduced the risk of cancer recurrence or death by 49% and distant metastasis or death by 59% compared to KEYTRUDA alone. It also showed encouraging overall survival trends and stronger immune responses driven by tumor-targeted T-cells. The therapy remained safe over long-term follow-up with mostly mild side effects, highlighting the potential of personalized cancer vaccines in future oncology care.
More
-
Jun 04 |
National group positions itself as key partner for biopharmaceutical research, strengthening its role in precision medicine
More
-
Jun 03 |
More
-
Jun 03 |
PrecisionLife, a leader in AI-driven precision medicine for chronic diseases, today announced the appointments of Dr Pradip Banerjee, PhD, MBA, as an Independent Non-Executive Director and Dr Kam Pooni, PhD, as Chief Product Officer. These strategic hires further strengthen the company’s leadership as it scales from a pioneering technology innovator to a commercial organization delivering real-world healthcare impact.
More
-
Jun 02 |
CRDMO successfully scaled and transferred Renaissance Pharma’s lead candidate, Daretabart a humanized monoclonal antibody targeting GD2 for high-risk neuroblastoma, in just 9 months.
More
-
Jun 01 |
CellCarta has announced a Strategic Partnership with Sonic to launch the first commercial laboratory relationship in CellCarta’s Lab Network strategy.
More
-
Jun 01 |
ClearNote Health today announced a $52M Series D financing alongside the appointment of Kevin Keegan as President and COO.
More
-
Jun 01 |
DNAnexus signals a bold new chapter in AI-powered precision health with several new product innovations and solution packages that extend its position as the purpose-built platform where the world's most scientifically complex data becomes the world's most powerful AI fuel.
More
-
Jun 01 |
New START site to be established in collaboration with Baptist Health Herbert Wertheim Cancer Institute will bring novel oncology therapies closer to patients across South Florida.
More
-
Jun 01 |
Ahead of BIO San Diego, Shilpa Biologicals urges biotech innovators to engage CDMO partners earlier and look beyond large-scale providers. Over-relying on a narrow network of large CDMOs increases the risk of scope creep, severe clinical trial delays, and budget overruns of up to 40%. Conversely, incorporating smaller CDMOs can lower costs and accelerate timelines from discovery to clinic by several months.
More
View more articles